Phase I Clinical Study of HY01 in Patients

• Status: Recruiting
• Trial end date: 2022-06-30

Summary

Phase I clinical study on the safety, tolerance, efficacy and pharmacokinetics of repeated intratympanic HY01 in patients with sudden sensorineural hearing loss. In this study, low-dose group and high-dose group were designed, 6 cases in each group.

• Phase: Phase 1

Details

• Lead Sponsor: Heyu (Suzhou) Pharmaceutical Technology Co., Ltd